Browsing Tag
IQVIA
14 posts
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.
Salesforce adds Viz.ai hospital triggers to Agentforce platform in pharma engagement push
Viz.ai and Salesforce are embedding real-time clinical triggers into Agentforce. Find out how this changes pharma go-to-market strategy in 2025.
Glenmark’s U.S. launch of Leucovorin Calcium for Injection: A strategic play in the generics arena
Find out how Glenmark Pharmaceuticals’ latest U.S. launch could reshape hospital generics in 2025. Will this move boost its global strategy?
Doceree launches RepTwin, an AI-powered solution to transform healthcare professional engagement at Fierce Pharma Week 2025
Doceree launches RepTwin at Fierce Pharma Week 2025, introducing an AI-powered virtual rep to transform pharmaceutical engagement with healthcare providers.
Lupin reports robust FY25 earnings with 71% profit growth and 600% dividend payout
Lupin posts 71% profit growth in FY25 with 600% dividend and strong U.S. performance. Find out how the pharma major is transforming its global footprint.
Alembic Pharmaceuticals secures final approval from FDA for hypertension drug
Alembic Pharmaceuticals Limited has successfully secured final approval from the US Food and Drug Administration (USFDA) for its…
Zydus Lifesciences bags FDA approval for Fludrocortisone Acetate Tablets, boosting U.S. market presence
Zydus Lifesciences Limited has secured final approval from the United States Food and Drug Administration (USFDA) to produce…
Zydus Lifesciences bags FDA tentative approval for Enzalutamide Tablets for prostate cancer treatment
Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its…
Zydus Lifesciences launches fight against prostate cancer with new FDA-approved drug enzalutamide
Zydus Lifesciences Limited has achieved a significant milestone in the pharmaceutical industry. The company recently received final approval…